 Edward Gardner
Concepts (263)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 46 | 2024 | 2720 | 3.650 |
Why?
| | Anti-HIV Agents | 23 | 2024 | 754 | 2.200 |
Why?
| | HIV Protease Inhibitors | 5 | 2019 | 68 | 1.580 |
Why?
| | HIV-1 | 13 | 2024 | 836 | 1.570 |
Why?
| | Anti-Retroviral Agents | 5 | 2021 | 231 | 1.520 |
Why?
| | Medication Adherence | 12 | 2019 | 558 | 1.410 |
Why?
| | Viral Load | 11 | 2024 | 448 | 1.200 |
Why?
| | Antiretroviral Therapy, Highly Active | 7 | 2017 | 267 | 1.020 |
Why?
| | HIV Integrase Inhibitors | 3 | 2024 | 69 | 0.970 |
Why?
| | Continuity of Patient Care | 3 | 2021 | 275 | 0.930 |
Why?
| | Tenofovir | 10 | 2024 | 231 | 0.930 |
Why?
| | Adenine | 10 | 2024 | 256 | 0.880 |
Why?
| | Patient Compliance | 5 | 2017 | 565 | 0.800 |
Why?
| | Drug Resistance, Viral | 5 | 2011 | 110 | 0.790 |
Why?
| | Organophosphates | 6 | 2020 | 120 | 0.620 |
Why?
| | Darunavir | 1 | 2019 | 18 | 0.620 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2019 | 31 | 0.610 |
Why?
| | Emtricitabine | 8 | 2019 | 168 | 0.590 |
Why?
| | Antiviral Agents | 5 | 2021 | 712 | 0.530 |
Why?
| | Mass Screening | 6 | 2024 | 1149 | 0.480 |
Why?
| | Healthcare Disparities | 1 | 2021 | 578 | 0.470 |
Why?
| | Emergency Service, Hospital | 6 | 2024 | 1902 | 0.460 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 2015 | 227 | 0.440 |
Why?
| | Health Services Administration | 1 | 2013 | 8 | 0.440 |
Why?
| | Alanine | 3 | 2024 | 142 | 0.430 |
Why?
| | Adult | 44 | 2025 | 35576 | 0.400 |
Why?
| | Public Health Administration | 1 | 2013 | 75 | 0.400 |
Why?
| | HIV | 4 | 2021 | 226 | 0.400 |
Why?
| | Male | 49 | 2025 | 63681 | 0.380 |
Why?
| | Pneumococcal Infections | 2 | 2024 | 110 | 0.380 |
Why?
| | Middle Aged | 37 | 2025 | 31154 | 0.380 |
Why?
| | Pyrrolidinones | 1 | 2011 | 29 | 0.370 |
Why?
| | CD4 Lymphocyte Count | 7 | 2019 | 266 | 0.370 |
Why?
| | Humans | 65 | 2025 | 129650 | 0.370 |
Why?
| | Streptococcus pneumoniae | 2 | 2024 | 159 | 0.370 |
Why?
| | Drug Therapy, Combination | 7 | 2021 | 1040 | 0.360 |
Why?
| | Female | 48 | 2025 | 68776 | 0.360 |
Why?
| | Hepatitis C | 3 | 2023 | 238 | 0.350 |
Why?
| | Reverse Transcriptase Inhibitors | 2 | 2008 | 83 | 0.350 |
Why?
| | Current Procedural Terminology | 1 | 2010 | 12 | 0.340 |
Why?
| | Fees and Charges | 1 | 2010 | 10 | 0.340 |
Why?
| | Pyridones | 2 | 2024 | 159 | 0.340 |
Why?
| | Patient Education as Topic | 3 | 2016 | 743 | 0.340 |
Why?
| | Dried Blood Spot Testing | 4 | 2019 | 94 | 0.340 |
Why?
| | Online Systems | 1 | 2009 | 21 | 0.330 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2010 | 82 | 0.320 |
Why?
| | Fibromyalgia | 1 | 2009 | 56 | 0.310 |
Why?
| | Drug Overdose | 3 | 2019 | 322 | 0.310 |
Why?
| | Antibodies, Neutralizing | 2 | 2021 | 265 | 0.310 |
Why?
| | Delivery of Health Care | 3 | 2014 | 894 | 0.310 |
Why?
| | Rheumatology | 1 | 2010 | 106 | 0.300 |
Why?
| | Clostridium butyricum | 1 | 2008 | 2 | 0.290 |
Why?
| | Organophosphonates | 3 | 2015 | 92 | 0.290 |
Why?
| | Deoxycytidine | 3 | 2015 | 165 | 0.280 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 569 | 0.280 |
Why?
| | Clostridium Infections | 1 | 2008 | 64 | 0.270 |
Why?
| | Naloxone | 3 | 2018 | 112 | 0.270 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2009 | 247 | 0.270 |
Why?
| | Narcotic Antagonists | 3 | 2018 | 164 | 0.260 |
Why?
| | Analgesics, Opioid | 4 | 2019 | 913 | 0.250 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 759 | 0.250 |
Why?
| | Health Care Costs | 2 | 2011 | 367 | 0.250 |
Why?
| | Kartagener Syndrome | 1 | 2005 | 30 | 0.240 |
Why?
| | Molecular Epidemiology | 1 | 2005 | 63 | 0.240 |
Why?
| | Treatment Outcome | 10 | 2023 | 10230 | 0.240 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2005 | 71 | 0.240 |
Why?
| | Macrolides | 1 | 2005 | 63 | 0.240 |
Why?
| | Lymphocyte Activation | 3 | 2021 | 1106 | 0.240 |
Why?
| | Blood Chemical Analysis | 3 | 2014 | 96 | 0.240 |
Why?
| | Prospective Studies | 12 | 2023 | 7133 | 0.230 |
Why?
| | Lymphopenia | 1 | 2025 | 59 | 0.230 |
Why?
| | Patient Acceptance of Health Care | 1 | 2011 | 759 | 0.230 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2005 | 61 | 0.230 |
Why?
| | Nasopharynx | 1 | 2024 | 67 | 0.230 |
Why?
| | Adenosine Monophosphate | 2 | 2021 | 63 | 0.230 |
Why?
| | Pre-Exposure Prophylaxis | 3 | 2017 | 203 | 0.230 |
Why?
| | Respiratory Tract Infections | 2 | 2024 | 376 | 0.220 |
Why?
| | Desiccation | 2 | 2014 | 20 | 0.220 |
Why?
| | Raltegravir Potassium | 2 | 2015 | 17 | 0.220 |
Why?
| | Abnormalities, Multiple | 1 | 2005 | 178 | 0.210 |
Why?
| | Retrospective Studies | 11 | 2024 | 14518 | 0.210 |
Why?
| | Hepacivirus | 3 | 2023 | 235 | 0.200 |
Why?
| | Specimen Handling | 2 | 2014 | 164 | 0.200 |
Why?
| | Sepsis | 1 | 2008 | 574 | 0.190 |
Why?
| | Cohort Studies | 5 | 2023 | 5420 | 0.180 |
Why?
| | Viremia | 2 | 2019 | 131 | 0.180 |
Why?
| | Vaccines, Conjugate | 1 | 2021 | 63 | 0.180 |
Why?
| | Substance-Related Disorders | 2 | 2018 | 1022 | 0.180 |
Why?
| | Arthritis, Rheumatoid | 1 | 2009 | 1092 | 0.170 |
Why?
| | Weight Gain | 1 | 2024 | 510 | 0.170 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2021 | 123 | 0.170 |
Why?
| | Internship and Residency | 1 | 2010 | 1053 | 0.170 |
Why?
| | Research Subjects | 1 | 2020 | 42 | 0.170 |
Why?
| | Adaptive Immunity | 1 | 2021 | 161 | 0.170 |
Why?
| | Pneumococcal Vaccines | 1 | 2021 | 140 | 0.160 |
Why?
| | Time-to-Treatment | 1 | 2021 | 180 | 0.160 |
Why?
| | Sexual and Gender Minorities | 2 | 2020 | 194 | 0.160 |
Why?
| | Gender Identity | 1 | 2020 | 122 | 0.160 |
Why?
| | Sustained Virologic Response | 1 | 2019 | 37 | 0.160 |
Why?
| | RNA, Viral | 3 | 2021 | 619 | 0.160 |
Why?
| | Oxazines | 1 | 2019 | 28 | 0.160 |
Why?
| | Leukocytes, Mononuclear | 3 | 2016 | 545 | 0.150 |
Why?
| | Colorado | 5 | 2018 | 4421 | 0.150 |
Why?
| | Rectum | 2 | 2016 | 170 | 0.150 |
Why?
| | Directly Observed Therapy | 1 | 2017 | 15 | 0.140 |
Why?
| | Atazanavir Sulfate | 2 | 2015 | 41 | 0.140 |
Why?
| | Terminology as Topic | 1 | 2019 | 204 | 0.140 |
Why?
| | Drug Administration Schedule | 4 | 2018 | 769 | 0.140 |
Why?
| | Homosexuality, Male | 2 | 2016 | 175 | 0.140 |
Why?
| | B-Lymphocytes | 2 | 2021 | 815 | 0.130 |
Why?
| | Microbiota | 1 | 2024 | 730 | 0.130 |
Why?
| | Genitalia | 1 | 2016 | 30 | 0.130 |
Why?
| | Piperazines | 1 | 2019 | 342 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2017 | 218 | 0.130 |
Why?
| | Chronic Pain | 2 | 2018 | 254 | 0.120 |
Why?
| | Genitalia, Female | 1 | 2015 | 38 | 0.120 |
Why?
| | Coinfection | 1 | 2016 | 131 | 0.120 |
Why?
| | Time Factors | 4 | 2016 | 6556 | 0.120 |
Why?
| | Mental Health Services | 1 | 2019 | 404 | 0.120 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 833 | 0.110 |
Why?
| | Young Adult | 10 | 2024 | 12426 | 0.110 |
Why?
| | Disease Transmission, Infectious | 1 | 2014 | 55 | 0.110 |
Why?
| | Biomarkers | 6 | 2021 | 3973 | 0.110 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 21 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2015 | 231 | 0.100 |
Why?
| | Vaccination | 1 | 2021 | 1348 | 0.100 |
Why?
| | United States | 4 | 2024 | 13903 | 0.100 |
Why?
| | Lamivudine | 1 | 2012 | 61 | 0.100 |
Why?
| | Zidovudine | 1 | 2012 | 78 | 0.090 |
Why?
| | Quality of Life | 2 | 2017 | 2704 | 0.090 |
Why?
| | Mental Disorders | 1 | 2019 | 1030 | 0.090 |
Why?
| | Population Surveillance | 1 | 2014 | 439 | 0.090 |
Why?
| | Intention to Treat Analysis | 2 | 2021 | 68 | 0.090 |
Why?
| | Lymphoma, AIDS-Related | 1 | 2010 | 14 | 0.090 |
Why?
| | Treatment Failure | 2 | 2021 | 340 | 0.080 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.080 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1928 | 0.080 |
Why?
| | Socioeconomic Factors | 1 | 2014 | 1214 | 0.080 |
Why?
| | Case-Control Studies | 3 | 2021 | 3381 | 0.080 |
Why?
| | Chromatography, Liquid | 3 | 2019 | 423 | 0.080 |
Why?
| | alpha 1-Antitrypsin | 1 | 2010 | 107 | 0.080 |
Why?
| | Risk Factors | 4 | 2021 | 9765 | 0.080 |
Why?
| | Adolescent | 8 | 2021 | 20393 | 0.080 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2009 | 87 | 0.080 |
Why?
| | Aged | 7 | 2025 | 22103 | 0.080 |
Why?
| | Public Health | 1 | 2013 | 484 | 0.080 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 524 | 0.080 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2016 | 1279 | 0.070 |
Why?
| | Comprehension | 1 | 2009 | 165 | 0.070 |
Why?
| | Oligopeptides | 1 | 2009 | 257 | 0.070 |
Why?
| | Cost Savings | 1 | 2008 | 78 | 0.070 |
Why?
| | Educational Status | 1 | 2009 | 470 | 0.070 |
Why?
| | Drug Costs | 1 | 2008 | 100 | 0.070 |
Why?
| | Disease Progression | 2 | 2023 | 2635 | 0.070 |
Why?
| | Double-Blind Method | 2 | 2021 | 1876 | 0.070 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 108 | 0.070 |
Why?
| | Anti-Bacterial Agents | 2 | 2008 | 1717 | 0.070 |
Why?
| | Catheterization, Central Venous | 1 | 2008 | 103 | 0.060 |
Why?
| | Osteomyelitis | 1 | 2008 | 122 | 0.060 |
Why?
| | Pyridines | 1 | 2009 | 478 | 0.060 |
Why?
| | Axonemal Dyneins | 1 | 2005 | 9 | 0.060 |
Why?
| | Inflammation | 1 | 2016 | 2736 | 0.060 |
Why?
| | HSP40 Heat-Shock Proteins | 1 | 2005 | 24 | 0.060 |
Why?
| | Dyneins | 1 | 2005 | 30 | 0.060 |
Why?
| | Liver Neoplasms | 1 | 2010 | 640 | 0.060 |
Why?
| | Nonlinear Dynamics | 1 | 2005 | 89 | 0.060 |
Why?
| | Analysis of Variance | 1 | 2008 | 1288 | 0.060 |
Why?
| | Mycobacterium avium Complex | 1 | 2005 | 88 | 0.060 |
Why?
| | Lymphocyte Count | 1 | 2025 | 148 | 0.060 |
Why?
| | Half-Life | 2 | 2016 | 162 | 0.060 |
Why?
| | Oropharynx | 1 | 2024 | 44 | 0.060 |
Why?
| | Nasal Mucosa | 1 | 2005 | 107 | 0.060 |
Why?
| | Genetic Linkage | 1 | 2005 | 299 | 0.060 |
Why?
| | Heat-Shock Proteins | 1 | 2005 | 136 | 0.060 |
Why?
| | Pilot Projects | 1 | 2009 | 1587 | 0.060 |
Why?
| | Gene Expression | 1 | 2009 | 1472 | 0.060 |
Why?
| | Aminobutyrates | 1 | 2024 | 33 | 0.060 |
Why?
| | Drug Substitution | 1 | 2024 | 51 | 0.060 |
Why?
| | Genotype | 1 | 2009 | 1839 | 0.060 |
Why?
| | Bronchiectasis | 1 | 2005 | 108 | 0.050 |
Why?
| | Curriculum | 1 | 2010 | 917 | 0.050 |
Why?
| | Spleen | 1 | 2005 | 507 | 0.050 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2009 | 1368 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 1838 | 0.050 |
Why?
| | Staphylococcal Infections | 1 | 2008 | 393 | 0.050 |
Why?
| | Triazoles | 1 | 2024 | 152 | 0.050 |
Why?
| | Multivariate Analysis | 1 | 2006 | 1502 | 0.050 |
Why?
| | Logistic Models | 1 | 2008 | 1988 | 0.050 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2024 | 525 | 0.050 |
Why?
| | Recurrence | 1 | 2005 | 1007 | 0.050 |
Why?
| | Primary Health Care | 3 | 2018 | 1680 | 0.050 |
Why?
| | Medical Futility | 1 | 2021 | 24 | 0.050 |
Why?
| | Hospitalization | 2 | 2021 | 2070 | 0.050 |
Why?
| | Ultrasonography | 1 | 2005 | 716 | 0.050 |
Why?
| | Inducible T-Cell Co-Stimulator Protein | 1 | 2021 | 9 | 0.050 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 27 | 0.050 |
Why?
| | Fatigue | 1 | 2023 | 318 | 0.050 |
Why?
| | Antigens, Viral | 1 | 2021 | 178 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2025 | 2742 | 0.040 |
Why?
| | Mutation | 1 | 2011 | 3717 | 0.040 |
Why?
| | Antibodies, Bacterial | 1 | 2021 | 137 | 0.040 |
Why?
| | Transsexualism | 1 | 2020 | 19 | 0.040 |
Why?
| | Plasma | 2 | 2012 | 206 | 0.040 |
Why?
| | Qualitative Research | 2 | 2016 | 1235 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2006 | 902 | 0.040 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2019 | 135 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2019 | 82 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4897 | 0.040 |
Why?
| | Odds Ratio | 1 | 2021 | 1023 | 0.040 |
Why?
| | Attitude of Health Personnel | 2 | 2016 | 1098 | 0.040 |
Why?
| | International Classification of Diseases | 1 | 2019 | 122 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2018 | 311 | 0.030 |
Why?
| | Longitudinal Studies | 2 | 2016 | 2717 | 0.030 |
Why?
| | Liver | 1 | 2005 | 1839 | 0.030 |
Why?
| | Cell Communication | 1 | 2018 | 301 | 0.030 |
Why?
| | Glucocorticoids | 1 | 2020 | 575 | 0.030 |
Why?
| | Spermatozoa | 1 | 2016 | 91 | 0.030 |
Why?
| | Ribavirin | 1 | 2016 | 91 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 521 | 0.030 |
Why?
| | Tomography, X-Ray Computed | 1 | 2005 | 2535 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2019 | 720 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 755 | 0.030 |
Why?
| | Blood | 1 | 2015 | 105 | 0.030 |
Why?
| | Comorbidity | 1 | 2019 | 1547 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 5066 | 0.030 |
Why?
| | Hepatitis C, Chronic | 1 | 2016 | 153 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1952 | 0.030 |
Why?
| | Risk | 1 | 2016 | 854 | 0.030 |
Why?
| | Models, Statistical | 1 | 2018 | 623 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2015 | 248 | 0.030 |
Why?
| | Mental Health | 1 | 2019 | 686 | 0.030 |
Why?
| | Focus Groups | 1 | 2015 | 453 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 412 | 0.030 |
Why?
| | Physicians, Primary Care | 1 | 2015 | 230 | 0.030 |
Why?
| | Dideoxynucleotides | 1 | 2012 | 14 | 0.020 |
Why?
| | Cytidine Triphosphate | 1 | 2012 | 14 | 0.020 |
Why?
| | Thymine Nucleotides | 1 | 2012 | 16 | 0.020 |
Why?
| | Self Report | 1 | 2016 | 799 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 3083 | 0.020 |
Why?
| | Food-Drug Interactions | 1 | 2010 | 9 | 0.020 |
Why?
| | Chemoprevention | 1 | 2010 | 91 | 0.020 |
Why?
| | Electronic Health Records | 1 | 2018 | 975 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2016 | 1065 | 0.020 |
Why?
| | Vincristine | 1 | 2010 | 109 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2010 | 232 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2010 | 300 | 0.020 |
Why?
| | Prednisone | 1 | 2010 | 233 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 3794 | 0.020 |
Why?
| | Drug Interactions | 1 | 2010 | 394 | 0.020 |
Why?
| | Ritonavir | 1 | 2009 | 73 | 0.020 |
Why?
| | Doxorubicin | 1 | 2010 | 325 | 0.020 |
Why?
| | Risk Assessment | 1 | 2018 | 3240 | 0.020 |
Why?
| | Clinical Competence | 1 | 2015 | 1017 | 0.020 |
Why?
| | Haplotypes | 1 | 2009 | 475 | 0.020 |
Why?
| | Erythrocytes | 1 | 2012 | 672 | 0.020 |
Why?
| | Animals | 1 | 2009 | 35361 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2009 | 779 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2009 | 640 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7086 | 0.020 |
Why?
| | Sex Factors | 1 | 2012 | 1968 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2832 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 5406 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 1565 | 0.010 |
Why?
|
|
Gardner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|